Author:
Chakraborty R,Muchtar E,Kumar S K,Buadi F K,Dingli D,Dispenzieri A,Hayman S R,Hogan W J,Kapoor P,Lacy M Q,Leung N,Warsame R,Kourelis T,Gonsalves W,Gertz M A
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference29 articles.
1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF et al SEER Cancer Statistics Review, 1975-2013. National Cancer Institute: Bethesda, MD, 2016. Available from https://seer.cancer.gov/statfacts/html/mulmy.html .
2. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770–1781.
3. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782–1791.
4. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.
5. Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C et al. Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III Myeloma XI Study. Blood 2016; 128: 1143–1143.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献